While knockdown of CDK5 with siRNA could alter cell growth and paclitaxel sensitivity in ovarian cancer cell lines with mutant TP53 (EFO21, EFO27, IGROV1, CAOV3, OAW42 and ES-2, SKOv3 and OC316) (Fig 1A), the most marked effects were observed in two ovarian cancer cell lines with wild type TP53 (HEY and A2780) (Fig 1A and 1B). Here, TP53 is linked to ovarian carcinoma.